Daily Brief Equity Bottom-Up: Taiwan Supply Chain Signals: Memory Revenue Re-Accelerates While Custom AI Chip Revenue Ramps and more

• Memory revenue re-accelerated well ahead of its seasonal pace: the six memory names grew revenue +32% MoM after about +4% in June, roughly twice their pace in July last year.
• Taiwan’s assemblers look weaker than they are: nine of thirteen ODM, EMS and PC-brand names saw revenue fall sequentially, yet the group beat its own July 2025 decline.
• Alchip Technologies (3661 TT)‘s revenue nearly quadrupled in two months and its filing reversed: after three months reporting mass-production declines, it reported growth, the only commentary change in our universe.

• The semiconductor pipeline has expanded to 15+ products and 10+ customers; Jubilant has also agreed to acquire 40% of Zettaone for INR 189.2 crore.
• Electronic chemicals can offer higher purity-led value addition, stickier qualifications and lower exposure to commodity chemical cycles.
• The semiconductor optionality is more tangible, but remains too early to underwrite as a major earnings driver without disclosed revenue or commercial volumes.

• Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.
• Highlights: Currently six pair trade opportunities persist across four markets and four sectors.
• Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.

• Market Position and High-Throughput Value Model: Lalithaa Jewellery Mart Limited (LALITHAA IN) is a prominent South Indian jewellery retailer operating 61 large-format showrooms across 51 cities. Its disruptive, ultra-low value-addition pricing strategy (making/wastage charges starting at 1-2%) drives an industry-leading store throughput of INR 410.23 Cr per showroom, propelling FY26 revenue to INR 250,239.27M (+48.1% YoY) and net income to INR 10,098.17M (+177.4% YoY).
• Working Capital Intensity and Cash Flow Dynamics: Despite strong top-line scaling and elevated FY26 return metrics (ROE of ~34.5% and ROCE of ~48.2%), the business model remains highly working capital intensive due to substantial gold inventory requirements (~INR 40-50 Cr per large-format store). Rapid network expansion resulted in negative operating cash flow of -INR 5,247.76M and free cash flow (FCFE) of -INR 5,923.44M in FY26.
• Valuation and Institutional Risk-Reward: At the current price of INR 265.24, Lalithaa trades at a P/E multiple of 12.2x and a P/B of 4.2x, presenting an attractive relative discount to regional peers such as P N Gadgil Jewellers (18.1x P/E). This valuation discount reflects thin core operating margins (4.04% net margin), high geographic concentration in South India, high promoter ownership (>80%), and ongoing tax/GST litigation contingencies.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Chinese domestic and outbound air travel activity rebounded sharply in July – why?
• If we’re right about the reasons for July’s recovery in traffic, bounce likely to be short-lived
• We expect platform Trip.com to confirm a weak outlook when it reports Q226 results

• Succession Tax Optimization Drives Yesterday’s Stake Gift: Chairman Lee Jang-han’s sudden gift of his entire 9.55% stake in Chong Kun Dang (CKD) Pharmaceutical to his three children on August 28, 2026, replicates the family’s September 2025 Kyongbo Pharmaceutical equity transfer. This is a strategic move to lock in succession tax liabilities while the “Korea Discount” keeps the company’s valuation depressed, bypassing the government’s newly tightened August 2026 price-suppression tax valuation rules.
• MOHW Pricing Reforms and Tactical Deferrals: The Ministry of Health and Welfare’s (MOHW) landmark decision on August 27, 2026, to delay generic drug price cuts (lowering the reimbursement ceiling from 53.55% to 45%) to April 2027 provides a critical six-month cash flow buffer. However, forward operating margins will inevitably compress toward 4.5% as CKD’s top-line is increasingly cannibalized by low-margin in-licensed co-promotions like Wegovy and Fexuclue.
• Severely Misaligned Capital Allocation vs. Value-Up: Despite government pressure to improve corporate governance, management has acted against minority shareholder interests, slashing the dividend per share from 1,100 won to 500 won in March 2026. Cash is being aggressively diverted to fund a massive 2.2 trillion won biopharmaceutical complex in Siheung, designed to build long-term legacy assets for the succession heirs rather than returning capital to public investors.

• Defensive Capital Structure Strategy: Samsung Biologics’ decision to fund the CHF 1.46 billion (KRW 2.71 trillion) PolyPeptide Group acquisition via a KRW 3.0 trillion rights offering protects its fortress balance sheet (debt-to-equity of 44% as of Q2 2026) and safeguards its AAA-equivalent domestic credit rating, neutralizing high-interest-rate borrowing risks while entering the high-margin peptide modality.
• M&A Integration Complexity: Integrating PolyPeptide AG represents a major operational departure from the Songdo “mega-plant” playbook. Moving from highly automated, centralized large-scale mammalian cell cultures to multi-site solid-phase peptide synthesis (SPPS) across Europe, the US, and India introduces cultural, labor, and process differences that cannot easily be standardized under the company’s proprietary ExellenS framework.
• Biosecure Act Windfall Execution: While the US Biosecure Act represents a massive tailwind, capturing this pipeline requires proactive tech transfers and commercial-scale validations, especially as major clients require dual-sourcing architectures. The acquisition of the 60,000-liter Rockville, Maryland facility for USD 280 million from GSK serves as a crucial onshore asset to satisfy domestic manufacturing requirements and secure late-stage clinical pipelines ahead of the 2032 grandfathering cliff.

• Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.
• Highlights: In Japan, currently two pair trade opportunities persist across two sectors.
• Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.

• Frontline PLC (NYSE: FRO) is capitalizing on structural tanker market tightness driven by global ton-mile expansion, sustained trade route realignments, and disciplined vessel supply growth, achieving its strongest operating profitability since 2004 with daily VLCC spot time charter equivalent (TCE) rates exceeding $100,000/day.
• The company maintains a high-specification, scrubber-fitted fleet across Very Large Crude Carriers (VLCCs), Suezmax, and LR2/Aframax segments, combining low cash breakeven operating leverage with a balanced commercial posture that secures ~30% of VLCC capacity under 1-year time charters while exposing 70% to spot freight super-spikes.
• Frontline offers compelling equity upside trading at 6.6x P/E and 7.2x EV/EBITDA, supported by robust balance sheet refinancing at reduced margins, accretive fleet renewal, and an active variable dividend policy that has delivered $2.58 per share in distributions across the first half of 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• STAR Market IPO and Financial Peak: YMTC’s historic RMB 33 billion STAR Market IPO application comes at a cyclical peak, with 1Q26 net profit reaching RMB 33.38 billion and gross margins surging to 76.77% on the back of rising NAND contract prices and high capacity utilization.
• Xtacking 4.0 and Density-Cost Trade-off: Mass production of 267-layer NAND under the Xtacking 4.0 architecture delivers industry-leading bit density by separating logic and memory array. However, this process requires bonding two separate wafers, resulting in a structurally higher baseline manufacturing cost that requires high yield rates to remain competitive.
• The Domestic Substitution Penalty: While YMTC’s Phase III fab has cleared a 50% domestic equipment threshold, reliance on localized etching and lithography workarounds imposes a persistent yield and throughput penalty of 5% to 10% compared to Western tool baselines.